Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan

Background: The therapy with biological disease-modifying anti-rheumatic drugs (bDMARDs) has proven to rapidly reduce articular symptoms/signs, decrease morbidities, and improve health outcome in patients with rheumatoid arthritis (RA) and be cost-effective in Western countries. However, the differe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Der-Yuan, Yu, Fun, Tuan, Li-Wen, Tang, Chao-Hsiun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818052/
https://www.ncbi.nlm.nih.gov/pubmed/31695611
http://dx.doi.org/10.3389/fphar.2019.01214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818052/
https://www.ncbi.nlm.nih.gov/pubmed/31695611
http://dx.doi.org/10.3389/fphar.2019.01214

Ejemplares similares